- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fullerton, California • Huntington Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced May 21, 2026, 7:59 PM EDT